[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thrombocytopenia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thrombocytopenia":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,50,79,109,138,165,194,217,252,276,304,326,348,378,405,427,464,484,508,535,558,592,612,630,650],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100645419","effect-of-platelet-concentrate-transfusion-on-microcirculatory-endothelial-function-in-intensive-care-unit-100645419",false,"NCT07682246","EFFECT OF PLATELET CONCENTRATE TRANSFUSION ON MICROCIRCULATORY ENDOTHELIAL FUNCTION IN INTENSIVE CARE UNIT","EFFECT OF PLATELET CONCENTRATE TRANSFUSION ON MICROCIRCULATORY ENDOTHELIAL FUNCTION IN INTENSIVE CARE UNIT.","PLATOMIR","Inclusion Criteria:\n\n* Adult patient ≥ 18 years of age\n* Admitted to intensive care\n* Requires prophylactic platelet transfusion for thrombocytopenia\n* Enrolled in a social security program\n* No objection to participating in the study\n\nExclusion Criteria:\n\n* Recent platelet or red blood cell transfusion (\\\u003C 24 hours)\n* Need for urgent red blood cell transfusion due to active bleeding\n* Patient under guardianship or conservatorship\n* Significant peripheral edema","ALL","18 Years",{"count":21,"type":22},60,"ESTIMATED","OBSERVATIONAL","This study aims to investigate the impact of platelet concentrate (PC) transfusions on endothelial function and the systemic inflammatory response in thrombopenic patients admitted to intensive care who require prophylactic platelet transfusions.\n\nEndothelial function will be measured using a laser Doppler device coupled with an acetylcholine iontophoresis system that is applied to the skin.",[26,27,28,29],"Thrombocytopenia","Prophylactic Platelet Transfusion","Platelet Transfusion","Endothelial Function",[31,32,28,29,33,34,35,36],"ICU","intensive care","endothelial biomarkers","systemic inflammation","oxidative stress","peripheral tissue perfusion","NOT_YET_RECRUITING","2026-06-26",{"date":40,"type":41},"2026-07-02","ACTUAL",{"date":43,"type":22},"2026-07",{"date":45,"type":22},"2027-07",{"name":47,"class":48},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":23,"phases":4,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100642137","role-of-viscoelastometric-testing-in-the-development-and-validation-of-a-clinical-biological-score-for-predicting-bleeding-in-patients-with-malignant-haematological-disorders-and-severe-thrombocytopenia-100642137","NCT07653672","Role of Viscoelastometric Testing in the Development and Validation of a Clinical-biological Score for Predicting Bleeding in Patients With Malignant Haematological Disorders and Severe Thrombocytopenia","VISCOTHEM-2","Inclusion Criteria:\n\n* Adult patients;\n* Who have been informed about the study and have freely given their informed consent to participate in the study;\n* With a malignant haematological disorder or bone marrow failure, whether treated or untreated and at any stage of treatment;\n* With central thrombocytopenia strictly below 20 G\u002FL in a blood sample taken less than 72 hours ago and not having received a transfusion since;\n* Admitted to a haematology day unit or inpatient ward, or being followed up at a haematology outpatient clinic;\n* With or without active bleeding;\n* Affiliated with or covered by a social security scheme.\n\nExclusion Criteria:\n\n* Patients who have received at least one of the following treatments:\n* Antiplatelet agents within 7 days prior to enrolment,\n* Vitamin K antagonists within 7 days prior to enrolment,\n* Direct oral anticoagulants within 72 hours prior to enrolment,\n* Low molecular weight heparin within 24 hours prior to inclusion,\n* Unfractionated heparin within 6 hours prior to inclusion,\n* Bruton's tyrosine kinase inhibitor (ibrutinib, zanubrutinib or acalabrutinib) within 72 hours prior to inclusion;\n* Patients with a history of thrombopathy;\n* Patients with a history of haemostatic disorders carrying a risk of haemorrhage or thrombosis;\n* Thrombocytopenia associated with immune thrombocytopenic purpura or disseminated intravascular coagulation;\n* Patients already enrolled in the study;\n* Pregnant or breastfeeding women;\n* Patients under guardianship or curatorship;\n* Patients who do not understand French;\n* Patients under judicial protection.",{"count":58,"type":22},410,"5 Days","The goal of this single-center, non-controlled, non-randomized exploratory clinical trial is To develop and validate a clinical-biological score (VISCOTHEM score) incorporating viscoelastometric tests parameters; based on an association study, and to establish a threshold that enables the prediction of the immediate risk of bleeding in haematology patients with severe thrombocytopenia (\\\u003C20 G\u002FL); with a view to selecting a population with a residual risk of bleeding of zero (NPV ≥ 95%, to achieve a residual probability of bleeding \\\u003C 5%).\n\nThe score may incorporate variables identified in the literature as having a plausible causal relationship with the occurrence of bleeding (14,15), as well as viscoelastometric tests parameters, conventional haemostasis parameters and relevant clinical parameters. .\n\nParticipants will undergo an additional blood sample to standard care. The total volume of blood drawn will be 21.1 mL. The following analyses will be performed: Quantra®, Rotem®, blood count, platelets, immature platelet count, plasma prothrombin time, activated partial thromboplastin time, International Normalized Ratio, fibrinogen, urea, creatinin, albumin.",[26,28,62,63],"Haemorrhage","Hematologic Malignancies",[65,66,67,68,69],"viscoelasticity test","thrombocytopenia","haematologic disease","risk of bleeding","clinical and laboratory score","2026-06-16",{"date":72,"type":41},"2026-06-17",{"date":74,"type":22},"2026-06-30",{"date":76,"type":22},"2028-07-15",{"name":78,"class":48},"Centre Hospitalier Annecy Genevois",{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":86,"minAge":19,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":49},"100640680","prediction-of-platelet-function-using-viscoelastic-test-rotem-sigma-in-obstetric-anesthesia-100640680","NCT07616349","Prediction of Platelet Function Using Viscoelastic Test (ROTEM® Sigma) in Obstetric Anesthesia.","Prediction of Platelet Function Using Viscoelastic Test (ROTEM® Sigma) in Obstetric Anesthesia: an Prospective Observational Study","Inclusion criteria:\n\n* Parturients with a suspicion or confirmed thrombocytopenia before delivery (platelet count \\\u003C 120x10\\^9\u002FL),\n* Parturients with severe postpartum haemorrhage (blood loss \\>1500 mL) with a suspicion of thrombocytopenia.\n\nExclusion criteria:\n\n* parturient age under 18 years;\n* refusal to participate","FEMALE",{"count":88,"type":22},85,"This prospective observational, non-interventional, single-center study aims to evaluate whether the viscoelastic parameter PLTEM, derived from ROTEM® sigma testing (EXTEM-A5 minus FIBTEM-A5), can accurately estimate platelet count in obstetric patients with thrombocytopenia and\u002For severe postpartum hemorrhage.\n\nThe study will include pregnant women older than 18 years managed during labor and delivery at the Hospital General Universitario Gregorio Marañón, Madrid (Spain).\n\nThe primary objective is to validate the clinical usefulness of PLTEM as a rapid point-of-care tool to support clinical decision-making regarding neuraxial anesthesia and transfusion management in obstetric emergencies.",[26,91],"Postpartum Haemorrhage (PPH)",[93,94,95,66,96,97,98],"Platelet function","viscoelastic test","Obstetric hemostasis","postpartum haemorrhage","PPH","ROTEM","RECRUITING","2026-05-29",{"date":102,"type":41},"2026-06-01",{"date":104,"type":41},"2026-05-01",{"date":106,"type":22},"2027-05-01",{"name":108,"class":48},"Nicolas Brogly",{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":119,"phases":120,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":49},"100423943","contribution-of-anti-platelet-antibodies-identified-with-maipa-assay-in-the-demonstration-of-the-auto-immune-character-of-a-thrombocytopenia-at-diagnosis-100423943","NCT04800458","Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis","Contribution of Anti-platelet Antibodies Identified With\" Monoclonal Antibody Immobilization of Platelet Antigens\" Assay (MAIPA) in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis","APAT","Inclusion Criteria:\n\n* Patient over 18 years old;\n* Patients with thrombocytopenia \\\u003C100 G\u002FL, checked twice, having ruled out false thrombocytopenia by platelet aggregation and acute leukemia by smear;\n* No treatment started;\n* Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and prior to any review required by the research);\n* Person affiliated or benefiting from a social security scheme.\n\nExclusion Criteria:\n\n* Secondary ITP;\n* False thrombocytopenia;\n* Patients who have been transfused with platelets for less than 7 days with efficacy;\n* Patient treated for thrombocytopenia (48 hours of corticosteroid therapy is tolerated and is not an exclusion criteria);\n* Patient with acute leukemia;\n* Pregnant or breastfeeding woman;\n* False thrombocytopenia;\n* Patient under guardianship, curatorship or any other legal protection regime.",{"count":118,"type":22},225,"INTERVENTIONAL",[121],"NA","Immune thrombocytopenia (ITP) is an autoimmune disease but, paradoxically, and unlike other autoimmune diseases, antiplatelet antibodies are not used either for the diagnosis of the disease or for its prognosis. ITP is a diagnosis of exclusion retained after elimination of other pathologies leading to a thrombocytopenia. No major study has prospectively evaluated the diagnostic value of the presence of anti-platelet antibodies in the etiological investigation of a thrombocytopenia, nor the impact of platelet antibodies on the course of ITP. The gold standard analysis for the determination of platelet antibodies, is the \"monoclonal antibody immobilization of platelet antigens\" assay (MAIPA), either direct to detect autoantibodies attached to platelets, or indirect to detect circulating antiplatelet antibodies. Therefore, this work aims to study the contribution of the presence of anti-platelet antibodies detected in MAIPA to determine the autoimmune nature of a thrombocytopenia at diagnosis.",[26,124,125],"Immune Thrombocytopenia","Myelodysplasia",[127,128,129,130],"Monoclonal antibody immobilization of platelet antigens assay","MAIPA","Anti-platelet antibodies","Thrombopoietin",{"date":102,"type":41},{"date":133,"type":41},"2021-05-19",{"date":135,"type":22},"2028-05",{"name":137,"class":48},"University Hospital, Bordeaux",{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":18,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":119,"phases":147,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":49},"100626906","phase-2-safety-and-efficacy-of-umbilical-cord-blood-therapy-for-cancer-therapy-induced-thrombocytopenia-ctit-100626906","NCT07441720","Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT)","Inclusion Criteria:\n\n1. Aged 12 to 65 years at the time of signing the informed consent, regardless of gender.\n2. Meets the diagnostic criteria for cancer treatment-induced thrombocytopenia (CTIT):Peripheral blood platelet count \\\u003C 100 × 10⁹\u002FL; Prior definite exposure to a chemotherapy agent (or tumor-targeted therapy, immunotherapy, or other anti-tumor drugs) known to cause thrombocytopenia, with gradual improvement of thrombocytopenia-related symptoms\u002Fsigns or normalization of platelet count after discontinuation of the offending drug; Presence or absence of bleeding tendency, such as petechiae, purpura, unexplained epistaxis, or even severe organ\u002Ftissue hemorrhage;\n3. No significant hepatic or renal impairment: ALT and AST ≤ 2.5 × upper limit of normal (ULN), serum creatinine (Cr) and blood urea nitrogen (BUN) ≤ 1.25 × ULN;\n4. Karnofsky Performance Status (KPS) score ≥ 60 (see Appendix 1), Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (see Appendix 2);\n5. Estimated life expectancy of more than 3 months.\n\nExclusion Criteria:\n\n1. Other causes of thrombocytopenia, in particular exclusion of underlying diseases or comorbidities such as aplastic anemia, acute leukemia, radiation sickness, immune thrombocytopenia (ITP), hypersplenism, or bone marrow infiltration by tumor cells;\n2. Use of non-anti-tumor medications known to cause thrombocytopenia (including but not limited to sulfonamides and other drugs);\n3. Pseudothrombocytopenia induced by ethylenediaminetetraacetic acid (EDTA) anticoagulant;\n4. Uncontrolled malignant tumor, hypertension, or diabetes mellitus;\n5. Active infection, including but not limited to known HIV positivity, active hepatitis B or C, or syphilis;\n6. Poor compliance;\n7. Known allergy or hypersensitivity to any component of the study intervention (umbilical cord blood or related products);\n8. Participation in another clinical trial within 1 month prior to enrollment or current participation in another clinical trial;\n9. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this clinical study.","12 Years","65 Years",{"count":7,"type":22},[148],"PHASE2","This study is a prospective, single-center, open-label, single-arm clinical trial to assess the safety and efficacy of umbilical cord blood in cancer treatment-induced thrombocytopenia (CTIT) patients. It plans to recruit subjects aged 12 to 65 years old with CTIT. The study involves intravenous infusion of umbilical cord blood, with platelet transfusion as supportive therapy if necessary. The trial consists of three phases: screening (baseline assessments and enrollment), treatment (umbilical cord blood infusion), and follow-up (blood routine tests at Days 3, 7, 14, and 28 post-treatment to record platelet counts, first response time, maximum and minimum values, and calculate efficacy rates while observing changes in thrombocytopenia grading). A total of 25 subjects will be enrolled, and they will undergo evaluation for safety and efficacy based on treatment-related adverse events, GVHD incidence, and hematological improvements.",[26,151],"Cancer Treatment-induced Thrombocytopenia",[153,154,155],"Umbilical cord blood","Cancer treatment-induced thrombocytopenia","CTIT","2026-05-05",{"date":158,"type":41},"2026-05-11",{"date":160,"type":41},"2026-02-28",{"date":162,"type":22},"2027-12-30",{"name":164,"class":48},"Zhejiang Cancer Hospital",{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":119,"phases":174,"briefSummary":176,"conditions":177,"keywords":181,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":49},"100584221","early-phase-1-apixaban-in-thrombocytopenia-100584221","NCT06886516","Apixaban in Thrombocytopenia","ADAPTiON: Apixaban Dose Adjustment in Patient With Thrombocytopenia in ONcology","Inclusion Criteria:\n\n* Active malignancy defined as histologically confirmed diagnosis within last 6 months or received any cancer directed therapy within the last 6 months.\n* Radiologically confirmed newly diagnosed symptomatic deep vein thrombosis or pulmonary embolism within 28 days of enrollment. Includes proximal lower-limb DVT or symptomatic PE. Upper extremity or catheter-associated thrombosis will be included, as will distal lower extremity DVTs.\n* Platelet count \\\u003C 75,000\u002Fml (prior to platelet transfusion) within 28 days of VTE diagnosis.\n* Platelet count responsive to transfusion if previously administered (defined as an average platelet increase of at least 10,000\u002Fml over the last 3 transfusions.\n* No evidence of active hemorrhage.\n* No recent history of major hemorrhage (requiring transfusion, hospitalization or intervention) within the last 12 months.\n* No known brain metastases.\n* Age ≥18 years. Because no dosing or adverse event data are currently available on the use of apixaban in participants \\\u003C18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.\n* ECOG performance status ≤2\n* Participants must have adequate organ and marrow function as defined below:\n\n  * Total bilirubin ≤ institutional upper limit of normal (ULN)\n  * AST(SGOT)\u002FALT(SGPT) ≤3 × institutional ULN\n  * Glomerular filtration rate (GFR) ≥25 mL\u002Fmin\u002F1.73\u002Fm2\n* Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n* For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* The effects of apixaban on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of apixaban administration.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants who are receiving any other investigational agents.\n* Participants who have had a thrombectomy, insertion of a caval filter, or require a fibrinolytic agent.\n* Participants that have index events with severe clot burden defined as bilateral proximal lower extremity deep vein thrombosis and saddle embolism or pulmonary embolism with hemodynamic compromise.\n* Participants with acute myeloid leukemia or myelodysplastic syndrome or who are undergoing or have undergone allogeneic stem cell transplant.\n* Participants with luminal gastrointestinal malignancy or genitourinary cancer.\n* Presence of known or prior brain metastasis, given the increased risk of life-threatening intracranial hemorrhage with anticoagulant use. While screening for brain metastases is not standard of care in this population, investigators may obtain brain imaging if clinically indicated prior to initiation of anticoagulation. Imaging is not mandated in order to participate in this study.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to apixaban.\n* Participants receiving any medications or substances that are inhibitors or inducers of CYP3A\u002FP-gp are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment\u002Finformed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.\n* Participants on aspirin (\\>100 mg\u002Fday), dual antiplatelet therapy, or receiving chronic treatment with NSAIDS\n* Participants with uncontrolled intercurrent illness.\n* Participants at high risk of bleeding such as:\n\n  * Unresected luminal\u002Fmucosal GI and GU cancers\n  * Active gastric or duodenal cancer\n  * History of major bleeding (based on ISTH criteria) in the past 12 months\n  * Any prior history of Intracranial hemorrhage (microhemorrhage is not included)\n  * Clinical or laboratory concern for ongoing DIC (prolonged PT\u002FAPTT or low fibrinogen)\n* Severe renal disease (CKD Stage IV or higher) or liver disease (Child Pugh B\u002FC)\n* Participants with pre-planned major surgery within the study period\n* Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because apixaban has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with apixaban, breastfeeding should be discontinued if the mother is treated with apixaban.\n* Participant must be able to swallow pills.",{"count":173,"type":22},30,[175],"EARLY_PHASE1","This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low number of platelets in the blood). Investigators are also looking to see if participants on this treatment have fewer bleeding episodes.\n\nThe name of the study drug involved in this study is:\n\n-Apixiban (a type of anticoagulant)",[178,179,26,180],"Deep Vein Thrombosis","Pulmonary Embolism and Thrombosis","Recurrent Venous Thromboembolism",[182,178,183,26,184,180],"Venous Thromboembolism","Pulmonary Embolism","Thromboembolism","2026-04-10",{"date":187,"type":41},"2026-04-15",{"date":189,"type":41},"2025-02-28",{"date":191,"type":22},"2029-07-01",{"name":193,"class":48},"Rushad Patell",{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":200,"enrollmentInfo":4,"targetDuration":4,"studyType":201,"phases":4,"briefSummary":202,"conditions":203,"keywords":204,"overallStatus":212,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":213,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":214,"locationsCount":4},"100426799","managed-access-programs-for-etb115-eltrombopag-100426799","NCT04837703","Managed Access Programs for ETB115, Eltrombopag","Inclusion Criteria:\n\nAn independent request was received from a licensed physician. The patient has a serious or life-threatening disease or condition and there is no comparable or satisfactory alternative therapy available for diagnosis, monitoring, or treatment.\n\nThe patient is not eligible or able to enrol in a clinical trial or continue participation in such trial.\n\nThere is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.\n\nThe patient must meet any other medical criteria established by the medical experts responsible for the product or by the health authority in the country of request (as applicable).\n\nProvision of the product will not interfere with the initiation, conduct, or completion of a Novartis clinical trial or overall development program.\n\nManaged Access provision is allowed per local laws\u002Fregulations.","99 Years","EXPANDED_ACCESS","The purpose of this registration is to list Managed Access Programs (MAPs) related to ETB115, Eltrombopag",[26],[205,66,206,207,208,209,210,211],"Eltrombopag","Idiopathic thrombocytopenic purpura","ITP","Severe aplastic anemia","SAA","HCV","Hepatitis C virus","AVAILABLE",{"date":187,"type":41},{"name":215,"class":216},"Novartis Pharmaceuticals","INDUSTRY",{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":224,"sex":18,"minAge":225,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":119,"phases":229,"briefSummary":230,"conditions":231,"keywords":237,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":251},"100568106","neonatal-platelet-transfusion-threshold-trial-100568106","NCT06676904","Neonatal Platelet Transfusion Threshold Trial","NeoPlaTT","Inclusion Criteria:\n\n* Gestational age of 23 0\u002F7 to 26 6\u002F7 weeks\n* Postnatal age of \\\u003C 48 hours\n\nExclusion Criteria:\n\n* Comfort care or withdrawal of care planned\n* Neonatal alloimmune thrombocytopenia or suspected\u002Fconfirmed congenital platelet or bleeding disorder\n* Receipt of platelet transfusion\n* No receipt of Vitamin K\n* Parents\u002Fguardian decline consent",true,"1 Hour","48 Hours",{"count":228,"type":22},2433,[121],"The objective of the NeoPlaTT trial is to test whether, among extremely preterm infants born at 23 0\u002F7 to 26 6\u002F7 weeks' gestation, a lower platelet transfusion threshold, compared to a higher threshold, improves survival without major or severe bleeding up to 40 0\u002F7 weeks' postmenstrual age (PMA).",[26,232,28,233,234,235,236],"Neonatal","Infant, Newborn, Diseases","Infant, Extremely Low Birth Weight","Infant, Small for Gestational Age","Thrombosis",[238,239,240],"platelet transfusion","neonatal","thrombosis","2026-03-24",{"date":243,"type":41},"2026-03-25",{"date":245,"type":41},"2025-06-13",{"date":247,"type":22},"2031-04-30",{"name":249,"class":250},"NICHD Neonatal Research Network","NETWORK",20,{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":119,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":49},"100576699","phase-2-luspatercept-for-clonal-cytopenias-of-uncertain-significance-100576699","NCT06788691","Luspatercept for Clonal Cytopenias of Uncertain Significance","Efficacy of Luspatercept In Clonal Cytopenias of Uncertain Significance","Inclusion Criteria:\n\n* Male or female ≥ 18 years of age.\n* Documentation of a CCUS diagnosis.\n\n  * Clonal cytopenia of undetermined significance (CCUS) is defined as clonal hematopoiesis of indeterminate potential (CHIP) detected in the presence of one or more persistent cytopenias that are otherwise unexplained by hematologic or non-hematologic conditions and that do not meet diagnostic criteria for defined myeloid neoplasms. Cytopenia definitions for diagnosis of CCUS include Hb \\\u003C13 g\u002FdL in males and \\\u003C12 g\u002FdL in females for anemia, absolute neutrophil count \\\u003C1.8 ×109\u002FL for leukopenia, and platelets \\\u003C150 × 109\u002FL for thrombocytopenia.\n  * Patients should harbor somatic mutations of myeloid malignancy-associated genes detected in the blood or bone marrow at a variant allele fraction (VAF) of ≥ 2% (≥4% for X-linked gene mutations in males\n* Clinically significant cytopenias demonstrated in two separate lab draws and defined as cytopenia in any one of the following:\n\n  * Anemia: Transfusion dependent (LTD or HTD for Hb \\\u003C 9 g\u002FdL based on IWG 2018 criteria). Exception for higher threshold up to 10g\u002FdL for documented moderate or severe angina pectoris, cardiac or pulmonary insufficiency, or ischemic neurologic diseases (per IWG 2018 consensus recommendation).\n  * Anemia NTD: symptomatic NTD CCUS with Hb \\\u003C10 g\u002Fdl, symptomatic defined as moderate or worse on ≥ 1 Patient Global Impression of Severity (PGI-S) item (fatigue, shortness of breath, weakness, or dizziness)\n  * Thrombocytopenia: platelet count less than 30,000 \u002FmicroL or \\\u003C 50,000\u002FmicroL with documented bleeding events or high risk for bleeding, for example on blood thinners or drugs that inhibit platelet function for other comorbidities.\n  * Neutropenia: Neutropenia below 750\u002Fmicrol are included in the study. For subjects with neutropenia between 750-1000\u002Fmicrol, subjects should have neutropenia AND a history of serious infection(s).\n* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2\n* Adequate organ function as defined by:\n\n  * Direct bilirubin \\\u003C 3 x ULN. Indirect hyperbilirubinemia from hemolysis or Gilberts disease are not considered as impaired.\n  * Estimated Creatinine clearance or GFR \\>30 ml\u002Fmin by institutional standards (for example MDRD or Cockcroft Gault or measured by 24 hour urine clearance).\n  * ALT and AST \\\u003C 3 x ULN\n* Females of childbearing potential (FCBP), defined as a sexually mature woman who: 1) has achieved menarche at some point, 2) not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy or amenorrhea due to other medical reasons does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months), must:\n\n  * Have two negative pregnancy tests (serum or urine) as verified by the investigator prior to starting study therapy (unless the screening pregnancy test was done within 72 hours of W1D1). She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment.\n  * Either commit to true abstinence1 from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, highly effective contraception2 without interruption, 5 weeks prior to starting investigational product, during the study therapy (including dose interruptions), and for 12 weeks after discontinuation of study therapy.\n\nMale subjects must:\n\n\\- Practice true abstinence1(which must be reviewed prior to each IP administration or on a monthly basis \\[e.g., in the event of dose delays\\]) or agree to use a condom (latex or non-latex, but not made out of natural \\[animal\\] membrane) during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 12 weeks following investigational product discontinuation, even if he has undergone a successful vasectomy.\n\nContraception\n\n* True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. \\[Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception\\].\n* Highly effective contraception is defined in this protocol as the following (information will also appear in the ICF): Hormonal contraception (for example, birth control pills, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation (tying your tubes); or a partner with a successful vasectomy.\n\nExclusion Criteria:\n\n* Concurrent malignancy requiring active concurrent systemic chemotherapy. Hormonal therapy for malignancy and targeted radiation is allowed. If patients after enrollment, have a clinical need for chemotherapy after achieving response on treatment, subjects deriving clinical benefit can be continued on study after discussion with study PI.\n* Diagnosis of MDS, AML, MPN or any other myeloid malignancy in the patient's lifetime\n* Active uncontrolled infection that in the investigators opinion will affect study procedures and\u002For results\n* Active uncontrolled hypertension not responding to blood pressure lowering medications which in the investigator's opinion will be harmful for the patient.\n* Use of ESA or growth factors within four weeks prior to the start of the study\n* Known risk factors for thromboembolism (splenectomy, concomitant use of hormone replacement therapy or recent uncontrolled pulmonary embolism or DVT in the last 6 months). Subjects adequately controlled on anticoagulation are permitted.\n* Pregnant or nursing women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using basic methods of contraception during dosing of study treatment and for up to 130 days after last dose of study drug. Basic contraception methods are defined in Section 4.4.\n\n  * Women are considered post-menopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks prior to first dose of study drug. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential. If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the Informed Consent Form (ICF).",{"count":260,"type":22},50,[148],"The purpose of this clinical trial is to test how well the drug luspatercept works in improving low blood cell counts in people with clonal cytopenias of uncertain significance (CCUS). The main questions the study seeks to answer include:\n\n* How many patients experience improvements in their low blood counts (red cells, platelets, or white cells) within 24 weeks, based on specific criteria for blood conditions like myelodysplastic syndromes (MDS)?\n* How long these improvements last before the condition worsens or changes.\n* The percentage of participants showing improvements at 12, 24, and 48 weeks.\n* How long it takes for the condition to progress to more severe diseases like myeloid disorders.\n* How long red blood cell responses last and how quickly these responses are seen.\n* The average change in hemoglobin levels over 24 weeks.\n* How many patients need blood transfusions during the study and how soon transfusions are required.\n* Changes in participants' well-being and energy levels based on a standardized questionnaire.\n* Monitoring for any side effects, including progression to MDS or leukemia, heart-related issues, or sudden increases in hemoglobin.\n\nParticipants will:\n\n* Receive luspatercept as an injection every three weeks.\n* Visit the clinic every three weeks for treatment and monitoring.",[264,265,266,26,267],"CCUS Clonal Cytopenia of Undetermined Significance","Anemia","Leukopenia","Neutropenia","2026-03-20",{"date":241,"type":41},{"date":271,"type":41},"2025-03-25",{"date":273,"type":22},"2028-02",{"name":275,"class":48},"Weill Medical College of Cornell University",{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":119,"phases":286,"briefSummary":288,"conditions":289,"keywords":291,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":49},"100626967","phase-3-comparison-of-etamsylate-versus-placebo-to-prevent-bleeding-in-hsct-100626967","NCT07442513","Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT","Comparison of Etamsylate Versus Placebo to Prevent Bleeding in Hematopoietic Stem Cell Transplantation Recipients：a Randomized, Double-blind, Phase 3, Clinical Study","Inclusion Criteria:\n\n1. Age between 18 and 70 years (inclusive), regardless of gender;\n2. Patients diagnosed with a hematological disease requiring hematopoietic stem cell transplantation;\n3. Expected platelet count ≤ 10 x 10⁹\u002FL persisting for 5 days or more;\n4. Normal coagulation function;\n5. Adequate organ function: Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 3 times the Upper Limit of Normal (ULN), Total Bilirubin ≤ 2 x ULN; Serum Creatinine ≤ 2 x ULN; Creatinine Clearance ≥ 50 mL\u002Fmin (calculated using the Cockcroft-Gault formula); Left Ventricular Ejection Fraction (LVEF) ≥ 50% as measured by Echocardiography (ECHO);\n6. Voluntary provision of signed informed consent, with the ability to understand and comply with all study requirements.\n\nExclusion Criteria:\n\n1. Diagnosis of acute promyelocytic leukemia confirmed according to WHO diagnostic criteria;\n2. Pregnant or breastfeeding women, and women of childbearing potential unwilling to use effective contraception;\n3. Presence of active bleeding or infection;\n4. History of diagnosed primary immune thrombocytopenia or hemolytic uremic syndrome;\n5. Patients with known hereditary or acquired hemorrhagic disorders;\n6. Patients receiving anticoagulant or antiplatelet therapy;\n7. Patients with severe cardiac insufficiency (left ventricular ejection fraction \\[EF\\] \\\u003C 60%); or severe arrhythmias: history of clinically significant QTc prolongation (male \\> 450 ms; female \\> 470 ms), ventricular tachycardia, atrial fibrillation, second-degree heart block; myocardial infarction within 1 year prior to enrollment; or symptomatic coronary artery disease requiring medication; patients with severe liver impairment (liver function indices \\[ALT, TBIL\\] \\> 3 times the upper limit of normal \\[ULN\\]);\n8. Patients with severe pulmonary insufficiency (obstructive and\u002For restrictive ventilatory defects);\n9. Patients with severe renal insufficiency (renal function index \\[Cr\\] \\> 2 times ULN); or 24-hour urinary creatinine clearance rate (Ccr) \\\u003C 50 ml\u002Fmin;\n10. Patients with mental disorders or other conditions preventing provision of informed consent and compliance with study treatment and procedural requirements;\n11. Other reasons deemed by the investigator to make the patient ineligible for inclusion.","70 Years",{"count":285,"type":22},404,[287],"PHASE3","This study employs a prospective, randomized, double-blind, placebo-controlled design. It aims to compare the efficacy of etamsylate versus placebo in preventing bleeding complications in patients with thrombocytopenia following hematopoietic stem cell transplantation.",[290,26],"Hematopoietic Stem Cell Transplantation",[292,293,66,294],"etamsylate","Hematopoietic Stem Cell Transplantation recipients","bleeding events","2026-02-25",{"date":297,"type":41},"2026-03-02",{"date":299,"type":41},"2025-12-16",{"date":301,"type":22},"2027-10-31",{"name":303,"class":48},"First Affiliated Hospital of Zhejiang University",{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":119,"phases":311,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":325},"100458852","phase-4-strategies-for-anticoagulation-in-patients-with-thrombocytopenia-and-cancer-associated-thrombosis-100458852","NCT05255003","STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis","Inclusion Criteria:\n\n1. Adult patients (age ≥ 18) with active malignancy (malignancy diagnosed or treated within the previous 6 months, or progressive\u002Frelapsed);\n2. Objectively confirmed VTE within last 14 days for which therapeutic anticoagulation is planned;\n3. Thrombocytopenia with a platelet count \\\u003C 50,000\u002FuL from cancer therapy or malignancy itself;\n4. Able to provide written informed consent\n\nExclusion Criteria:\n\n1. Receipt of anticoagulant for index VTE with platelet count \\\u003C 50,000\u002FuL for \\> 72 hours;\n2. Superficial vein thrombosis only;\n3. Life expectancy \\\u003C 1 month (as judged by the treating physicians);\n4. Creatinine clearance \\\u003C 30 ml\u002Fmin;\n5. Contraindication to LMWH such as a history of heparin induced thrombocytopenia;\n6. Thrombocytopenia from other causes, such as thrombotic microangiopathy, immune thrombocytopenia, disseminated intravascular coagulation;\n7. Previously documented history of refractoriness to platelet transfusion secondary to HLA antibodies;\n8. Refusal of blood products;\n9. Anticoagulation at any dose is deemed unsafe (i.e. active bleeding or bleeding disorders)",{"count":260,"type":22},[312],"PHASE4","Patients with cancer are prone to have blood clots, which are usually treated with blood thinners. The main complication of blood thinners is bleeding. This is especially a concern when the number of platelets in the blood is lower than 50,000 per microliter. The role of platelets is to stop bleeding, so when the number of platelets is low, patients are at a higher risk of bleeding. Cancer patients are prone to have lower platelet numbers due to cancer therapies and\u002For cancer itself. It is not clear what the best treatment is for cancer patients who need blood thinners for a blood clot but have low platelet counts.\n\nThe investigators plan to do a small study called a pilot study to help plan for a larger study in such patients. In the pilot study, investigators will include 50 patients with cancer, low platelet counts, and a blood clot diagnosed within 2 weeks. Patients will be randomly assigned to one of the two treatment strategies: the full dose of blood thinners along with platelet transfusion or a reduced dose of blood thinners without platelet transfusion. The investigators will follow all patients for 30 days. If this pilot study is successful, it will help lead to a much larger trial, which will provide important information on the best treatment strategy for these patients.",[315,26],"Cancer-associated Thrombosis","2025-12-09",{"date":318,"type":41},"2025-12-17",{"date":320,"type":41},"2022-08-29",{"date":322,"type":22},"2027-01-31",{"name":324,"class":48},"Tzu-Fei Wang",4,{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":119,"phases":336,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":49},"100612763","phase-2-herombopag-treated-t-dm1-induced-platelet-reduction-100612763","NCT07257809","Herombopag Treated T-DM1 Induced Platelet Reduction","A Multicenter, Single-arm Exploratory Clinical Study Evaluating the Efficacy and Safety of T-DM1 in Patients With Breast Cancer Who Developed Thrombocytopenia.","Inclusion：\n\n* Age 18-75 years, any gender;\n* Pathologically diagnosed with breast cancer based on histological or cytological examination, and previously treated with neoadjuvant anti-HER-2 therapy followed by T-DM1 adjuvant therapy;\n* Experienced grade 2 or higher tumor treatment-related thrombocytopenia during the previous T-DM1 treatment cycle, with platelet count restored to ≥100 × 109\u002FL and ≤200 × 109\u002FL prior to the next treatment;\n* ECOG performance status score: 0-2;\n* Planned to undergo at least two additional treatment cycles including T-DM1 administration, with the dose of T-DM1 in the current cycle consistent with the previous cycle;\n* Expected survival of ≥12 weeks and able to tolerate the current treatment regimen for at least two cycles or more;\n* Expected to have good compliance, able to follow up on treatment efficacy and adverse reactions as required by the protocol.\n\nExclusion:\n\n* A history of other malignant tumors diagnosed within the past 3 years;\n* Patients with mental or neurological disorders who are unable to cooperate;\n* Patients who are scheduled to undergo or have previously undergone organ or bone marrow transplantation;\n* Patients with hematopoietic system disorders other than chemotherapy-induced thrombocytopenia (CTIT), including but not limited to leukemia, primary immune thrombocytopenia, myeloproliferative disorders, multiple myeloma, and myelodysplastic syndrome;\n* Patients with a history of any arterial or venous thrombotic events within the past 6 months prior to screening;\n* Severe bleeding manifestations within 2 weeks prior to screening, such as gastrointestinal or central nervous system bleeding;\n* Participation in a clinical trial of the same type of drug within 4 weeks prior to enrollment;\n* Pregnant or lactating women;\n* Patients with a history of hypersensitivity to the study drug;\n* Patients deemed ineligible by the investigator.","75 Years",{"count":335,"type":22},56,[148],"This is a single-arm study planned to enroll 56 breast cancer patients who experienced grade 2 or higher thrombocytopenia following prior chemotherapy and achieved normalization (platelet count ≥100 × 109\u002FL and ≥200 × 109\u002FL) through intervention.",[26],"2025-11-27",{"date":341,"type":41},"2025-12-02",{"date":343,"type":41},"2025-10-13",{"date":345,"type":22},"2027-09-26",{"name":347,"class":48},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":18,"minAge":356,"maxAge":357,"enrollmentInfo":358,"targetDuration":4,"studyType":119,"phases":360,"briefSummary":361,"conditions":362,"keywords":364,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":377},"100493924","platelet-directed-whole-blood-transfusion-strategy-for-malaria-100493924","NCT05711485","Platelet-Directed Whole Blood Transfusion Strategy for Malaria","Clinical and Translational Investigations of Severe Malaria Pathophysiology [Parent Study Protocol]","PLATFORM","Inclusion Criteria:\n\n* Age \\\u003C5 years\n* Platelet count ≤75,000\u002FuL\n* Hemoglobin \\>5 and ≤9 g\u002FdL\n* P. falciparum parasitemia ≥500 parasites\u002FuL\n* Diagnosis of severe malaria meeting World Health Organization (WHO) criteria\n* Ability and willingness of the legal guardian to comply with study protocol for the duration of the study\n* Residence within health clinic catchment area\n* Signed informed consent obtained from the parent or legal guardian of the participant\n\nExclusion Criteria:\n\n* Residence in foster care or children otherwise under government supervision\n* Residence outside the hospital catchment area, or plan to leave the area\n* Presence of any other condition or abnormality which, in the opinion of the investigator, would compromise the safety of the participant or the quality of the data\n* Any contraindication to whole blood transfusion","6 Months","59 Months",{"count":359,"type":22},132,[121],"Open-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.",[363,26],"Severe Malaria",[365,366,367],"Malaria","Plasmodium falciparum","Zambia","2025-10-07",{"date":370,"type":41},"2025-10-09",{"date":372,"type":41},"2024-02-24",{"date":374,"type":22},"2028-05-31",{"name":376,"class":48},"Johns Hopkins Bloomberg School of Public Health",2,{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":384,"enrollmentInfo":385,"targetDuration":4,"studyType":119,"phases":387,"briefSummary":388,"conditions":389,"keywords":392,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":49},"100607233","a-multicenter-open-label-randomized-controlled-trial-evaluating-the-efficacy-and-safety-of-romiplostim-n01-in-the-treatment-of-thrombocytopenia-associated-with-concurrentsequential-chemoradiotherapy-and-chemotherapy-combined-withwithout-immunotherapy-in-solid-tumors-100607233","NCT07185893","A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent\u002FSequential Chemoradiotherapy and Chemotherapy Combined With\u002FWithout Immunotherapy in Solid Tumors","Inclusion Criteria:\n\n1. Age:18 to 80 years old (man or female);\n2. Confirmed with solid tumor by pathological histology or cytology examination;\n3. The patient is undergoing concurrent\u002Fsequential radiotherapy ± immunotherapy;\n4. During the treatment period, the patient experienced a decrease in platelets, and the platelet count within the last 3 days before enrollment was 25×10\\^9\u002FL \\\u003C platelet count ≤ 75×10\\^9\u002FL;\n5. The estimated survival period at screening is ≥ 3 months, and it is expected that the current chemotherapy cycle can be used for ≥ 2 cycles;\n6. ECOG 0 - 2;\n7. Fully understand and comply with the requirements of this study, and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. Platelet count ≤ 25×10\\^9\u002FL at baseline;\n2. The patient has previously received treatments for thrombocytopenia, such as thrombopoietin receptor agonists (TOP-RA), recombinant human thrombopoietin (rhTPO), or rhIL-11, etc.;\n3. Patients with hematological disorders, including lymphoma, leukemia, aplastic anemia, primary immune thrombocytopenia, myelodysplastic syndromes, multiple myeloma, and myelodysplastic syndrome, etc.;\n4. Have experienced thrombocytopenia due to non-tumor treatment within the past 6 months, including but not limited to EDTA-dependent pseudo-thrombocytopenia, splenomegaly, infection, bleeding, etc.;\n5. After red blood cell or erythropoietin (EPO) infusion, hemoglobin is still \\\u003C 50g\u002FL, or after granulocyte colony-stimulating factor (G-CSF) treatment, absolute neutrophil count is still \\\u003C 1.0×10\\^9\u002FL;\n6. Have experienced any arterial or venous thrombosis within the past 6 months;\n7. Have suffered from severe cardiovascular diseases (such as NYHA cardiac function class III-IV), increased risk of thrombosis-related arrhythmias (such as atrial fibrillation), coronary artery stent implantation, angioplasty, and coronary artery bypass grafting within the past 6 months;\n8. Have received platelet transfusion within 5 days before randomization or enrollment;\n9. Patients with positive hepatitis C antibody and excessive HCV-RNA detection, positive hepatitis B surface antigen and excessive HBV-DNA detection, patients with severe cirrhosis, positive HIV antibody, or positive syphilis antibody;\n10. During screening, for subjects without liver metastasis, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are ≥ 3 times ULN; for subjects with liver metastasis, ≥ 5 times ULN;\n11. Serum creatinine concentration ≥ 1.5 times ULN or eGFR ≤ 60ml\u002Fmin;\n12. Patients who are allergic or intolerant to the active ingredient or excipients of Romiplostim N01 for injection;\n13. Planning to get pregnant or in the lactation period;\n14. The investigator determines that the patient is not suitable to participate in this trial.","80 Years",{"count":386,"type":22},106,[121],"The purpose of this clinical trial is to evaluate the safety and efficacy of Romiplostim N01 in patients with solid tumors who are undergoing concurrent\u002Fsequential radiotherapy and chemotherapy（combined with\u002Fwithout immunotherapy）-related thrombocytopenia.\n\nAll eligible patients will be stratified and randomly assigned based on baseline platelet count（Stratification factors: whether the baseline platelet count of the patients is greater than 50×10\\^9\u002FL. ） . All patients will be randomly assigned in a 1:1 ratio to experimental group or control group:\n\nExperimental group: Romiplostim N01 (N=53) Control group：Human Interleukin-11(rhlL-11) (N=53) The main questions this trial aims to answer are: 1. The proportion of patients who received platelet transfusion due to thrombocytopenia during the treatment process, as well as the adjustment, delay and discontinuation of radiotherapy and chemotherapy doses； 2. Can patients treated with Romiplostim N01 restore their platelet count to ≥ 100×10\\^9\u002FL and what is the response rate of patients during the treatment (response criteria: no need for platelet transfusion and PLT increase ≥ 50×10\\^9\u002FL or at least twice the baseline or PLT increase to ≥ 100×10\\^9\u002FL)；3. The safety and tolerance of Romiplostim N01 in treating CTIT.",[390,391,26],"Solid Tumor Malignancies, Cancer","CTIT-Chemotherapy Induced Thrombocytopenia",[393,394,395,66,155],"Romiplostim N01","Human Interleukin-11","solid tumor","2025-09-15",{"date":398,"type":41},"2025-09-22",{"date":400,"type":22},"2025-09",{"date":402,"type":22},"2028-12-31",{"name":404,"class":48},"Jun wang",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":333,"enrollmentInfo":412,"targetDuration":4,"studyType":119,"phases":414,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":425,"locationsCount":49},"100601407","phase-1-umbilical-cord-blood-megakaryocyte-injection-xj-mk-002-for-cancer-therapy-induced-thrombocytopenia-ctit-100601407","NCT07110090","Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT)","A Dose-Escalation Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) in Patients With Cancer Therapy-Induced Thrombocytopenia (CTIT)","Inclusion Criteria:\n\n1. Subjects aged 18 to 75 years (inclusive) at the time of signing the informed consent, regardless of gender.\n2. Histologically and\u002For cytologically confirmed diagnosis of a malignant tumor, with thrombocytopenia due to anti-tumor treatments (e.g., chemotherapy, immunotherapy, targeted therapy, and radiotherapy), 50×10⁹\u002FL≤platelet count (PLT) is ≤100×10⁹\u002FL, confirmed by blood tests (with reconfirmation on the day prior to infusion) and with no bleeding\n3. No transfusion of platelets or blood products containing platelet components within 72 hours prior to investigational product administration.\n4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.\n5. Estimated life expectancy of more than 3 months.\n6. Female subjects of childbearing potential (WOCBP) and male subjects with WOCBP partners must agree to use highly effective contraception methods in accordance with ICH M3 (R2) guidelines during the trial and for 6 months after administration. Male subjects must also agree not to donate sperm during this period. WOCBP must have a negative pregnancy test result within 7 days prior to enrollment.\n\nExclusion Criteria:\n\n1. History of platelet transfusion refractoriness.\n2. History of severe allergic reactions related to blood transfusion.\n3. History of bleeding disorders or thrombocytopenia caused by conditions other than CTIT.\n4. Splenomegaly or hypersplenism.\n5. Use of thrombopoietin-stimulating drugs within 7 days prior to receiving the investigational product, including recombinant human thrombopoietin (rhTPO), recombinant human interleukin-11 (rhIL-11), romiplostim, eltrombopag, hetrombopag, leucogen tablets, aminopeptidase tablets, and caffeic acid tablets.\n6. Subjects with existing severe bleeding (e.g., cerebral hemorrhage, severe gastrointestinal bleeding, or severe hemoptysis).\n7. Subjects with hemophilia or coagulation disorders.\n8. History of thromboembolic diseases (deep vein thrombosis, arterial thrombosis) within 6 months before screening, or patients with catheter-related thrombosis within 1 month before screening.\n9. History of cardiac diseases within 3 months before screening, or a history of severe cardiovascular diseases (e.g., congestive heart failure (NYHA Class 3\u002F4), known arrhythmias that increase the risk of thromboembolic events (e.g., atrial fibrillation, atrial flutter, unstable angina), coronary stent placement, angioplasty, or coronary artery bypass grafting).\n10. Major organ surgery (excluding needle biopsy) or severe trauma within 4 weeks before administration of the investigational product or anticipated major surgery during the trial.\n11. Use of anticoagulant drugs within 7 days before screening, including vitamin K antagonists, low molecular weight heparin (except for minimal heparin use for catheter locking), factor Xa inhibitors (e.g., rivaroxaban), thrombin inhibitors, and\u002For antiplatelet therapy (e.g., aspirin).\n12. Coagulation function abnormalities: activated partial thromboplastin time (APTT) \\>1.5× upper limit of normal (ULN); international normalized ratio (INR) \\>1.5×ULN.\n13. Liver and kidney function abnormalities: liver function (for non-liver cancer patients or those without liver metastasis): total bilirubin (TBIL) \\>2.5×ULN, alanine aminotransferase (ALT) \\>2.5×ULN, aspartate aminotransferase (AST) \\>2.5×ULN; renal function: creatinine clearance (Ccr) \\\u003C50 mL\u002Fmin, or serum creatinine (Cr) \\>1.5×ULN.\n14. Complete blood count abnormalities: Absolute neutrophils count \\\u003C1.0×109\u002FL, hemoglobin \\\u003C80g\u002FL (use of erythropoietin infusion therapy according to clinical standards is allowed during screening).\n15. Positive serology tests during screening: positive anti-HIV antibody or anti-treponema pallidum specific antibody test; or positive hepatitis C antibody with HCV RNA copy number above the upper limit of normal, positive hepatitis B surface antigen, or history of hepatitis B infection; or positive hepatitis B core antibody with HBV-DNA ≥2000 IU\u002FmL within the last 3 months before screening.\n16. Uncontrolled severe chronic or active infection requiring intravenous antibiotic treatment before administration.\n17. Subjects with known allergies to the investigational product, its active ingredients, or any of its excipients.\n18. Use of any investigational product with a similar mechanism of action within 4 weeks prior to administration of the investigational product, or current participation in another clinical trial (except for observational, non-interventional clinical trials, or the follow-up period of an interventional clinical trial).\n19. History of hematopoietic stem cell transplantation with acute graft-versus-host disease requiring therapeutic intervention.\n20. Pregnant or lactating female subjects.\n21. Any other medical condition that, in the investigator's judgment, precludes participation in this study or completion of follow-up observations.",{"count":413,"type":22},16,[415],"PHASE1","This study is a single-center, open-label, single-arm, dose-escalation clinical trial to assess safety \\& tolerability of XJ-MK-002 in CTIT patients. It plans to recruit subjects aged 18 to 75 years old with chemotherapy-induced thrombocytopenia (CTIT). The study is designed with three dose levels: low dose (1.0×108 viable cells per person), medium dose (3.0×108 viable cells per person), and high dose (6.0×108 viable cells per person). The first dose group (low dose) will enroll one subject for accelerated titration, while the other two dose groups will enroll at least three subjects each. Subjects successfully enrolled will receive only one cell therapy session. After the cell therapy, they will undergo a 28-day dose-limiting toxicity (DLT) observation period.",[26,418],"Cancer","2025-09-03",{"date":421,"type":41},"2025-09-09",{"date":423,"type":41},"2025-08-28",{"date":43,"type":22},{"name":426,"class":48},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":333,"enrollmentInfo":435,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":437,"conditions":438,"keywords":444,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":4},"100601248","hematological-disorders-in-ehpvo-patients-100601248","NCT07108023","Hematological Disorders in EHPVO Patients","A Prospective Study of the Spectrum of Haematological Disorders in Patients With Extrahepatic Portal Vein Obstruction","EHPVO-HEM","Inclusion Criteria:\n\n* Age 18 years or older . Diagnosis of extra hepatic portal vein obstruction based on imaging ( Doppler, CT , MRI ) preserved liver function . Available complete medical records including CBC , LFTs and coagulation profile .\n\nExclusion Criteria:\n\n* Patients with cirrhosis or intrahepatic portal hypertension • Incomplete or missing medical records • Patients with known hematologic malignancies or undergoing chemotherapy",{"count":436,"type":22},115,"This study focuses on patients who have a condition called extrahepatic portal vein obstruction (EHPVO), where a blood clot blocks the portal vein outside the liver. This blockage can cause problems like an enlarged spleen, bleeding from swollen veins in the digestive system, and low blood cell counts. Many of these patients may have hidden blood disorders that increase the risk of clotting, such as myeloproliferative neoplasms (MPNs), antiphospholipid syndrome (APS), or paroxysmal nocturnal hemoglobinuria (PNH). This study will collect and analyze blood test results-such as complete blood count (CBC), liver function tests (LFTs), and clotting tests-from patients with EHPVO. The aim is to find patterns that may suggest an underlying blood disorder, even if the patient doesn't show obvious symptoms.By understanding these patterns early, doctors may be able to diagnose and treat the root causes of clotting in these patients more accurately, helping prevent complications and improve outcomes.",[439,440,441,442,443,26,265,266],"Extrahepatic Portal Vein Obstruction (EHPVO)","Thrombophilia","Myeloproliferative Neoplasms (MPN)","Antiphospholipid Syndrome (APS)","Paroxysmal Nocturnal Hemoglobinuria (PNH)",[445,446,447,448,449,450,451,452,453,454],"Portal vein thrombosis","EHPVO","Hypersplenism","Hematological disorders","Coagulation profile","Liver function tests","CBC","JAK2 mutation","Thrombosis in MPN","Cross-sectional study","2025-07-31",{"date":457,"type":41},"2025-08-06",{"date":459,"type":22},"2025-08",{"date":461,"type":22},"2025-12",{"name":463,"class":48},"Rahab Nady",{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":119,"phases":473,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":482,"locationsCount":49},"100514857","phase-2-anti-cd38-antibody-treating-aps-with-thrombocytopenia-100514857","NCT05983952","Anti-CD38 Antibody Treating APS With Thrombocytopenia","A Prospective, One-arm and Open Clinical Study to Assess Safety and Efficacy of Anti-CD38 Antibody in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia","Inclusion Criteria:\n\n* Age 18 and above, male or female.\n* Conform to the diagnostic criteria of antiphospholipid syndrome (APS).\n* Failure to achieve response or relapse after corticosteroid therapy, and at least one second-line therapy including rituximab, CSA or CTX etc., or those who cannot chose other second-line therapy.\n* Platelet count of \\\u003C30 X 10\\^9\u002FL.\n* With normal hepatic and renal functions.\n* ECOG physical state score ≤ 2 points.\n* Cardiac function of the New York Society of Cardiac Function ≤ 2.\n* Signed and dated written informed consent\n\nExclusion Criteria:\n\n* Received any treatment of anti-CD38 antibody drug\n* Uncontrollable primary diseases of important organs, such as malignant tumors, liver failure, heart failure, renal failure and other diseases;\n* HIV positive;\n* Accompanied by uncontrollable active infection, including hepatitis B, hepatitis C, cytomegalovirus, EB virus and syphilis positive;\n* Accompanied by extensive and severe bleeding, such as hemoptysis, upper gastrointestinal hemorrhage, intracranial hemorrhage, etc.;\n* At present, there are heart diseases, arrhythmias that need treatment or hypertension that researchers judge is poorly controlled;\n* Patients with thrombotic diseases such as pulmonary embolism, thrombosis and atherosclerosis;\n* Those who have received allogeneic stem cell transplantation or organ transplantation in the past;\n* Patients with mental disorders who cannot normally obtain informed consent and conduct trials and follow-up;\n* Patients whose toxic symptoms caused by pre-trial treatment have not disappeared;\n* Other serious diseases that may limit the subject's participation in this test (such as diabetes; Severe cardiac insufficiency; Myocardial obstruction or unstable arrhythmia or unstable angina pectoris in recent 6 months; Gastric ulcer, etc.);\n* Patients with septicemia or other irregular severe bleeding;\n* Pregnant women, suspected pregnancies (positive pregnancy test for human chorionic gonadotropin in urine at screening) and lactating patients.",{"count":472,"type":22},10,[148],"To evaluate the safety and efficacy of anti-CD38 antibody in the treatment of antiphospholipid syndrome with secondary thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including rituximab and\u002For TPO-RA.",[476,26],"Antiphospholipid Syndrome",{"date":478,"type":41},"2025-08-05",{"date":480,"type":41},"2023-08-01",{"date":459,"type":22},{"name":483,"class":48},"Institute of Hematology & Blood Diseases Hospital, China",{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":491,"enrollmentInfo":492,"targetDuration":4,"studyType":119,"phases":494,"briefSummary":495,"conditions":496,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":504,"leadSponsor":506,"locationsCount":49},"100542954","optimizing-pulsatility-during-cardiopulmonary-bypass-to-reduce-acute-kidney-injury-100542954","NCT06349577","Optimizing Pulsatility During Cardiopulmonary Bypass to Reduce Acute Kidney Injury","Optimizing Pulsatility During Cardiopulmonary Bypass to Reduce Acute Kidney Injury: Randomized Controlled Trial","Inclusion Criteria:\n\n* Able to provide informed consent\n* Scheduled for elective cardiac surgery with cardiopulmonary bypass\n\nExclusion Criteria\n\n* Emergency procedures\n* Scheduled for heart or lung transplantation\n* Scheduled for ventricular assist device implantation\n* Use of the Medtronic Elongated Once-Piece Arterial Cannula\n* Diagnosed with sepsis\n* Diagnosed with delirium\n* Experiencing hemodynamic instability (heart rate \\> 100 and systolic blood pressure \\\u003C 90)\n* Requiring mechanical circulatory support\n* Requiring vasoactive medications","85 Years",{"count":493,"type":22},1100,[121],"The objective is to determine the effectiveness of pulsatile flow during cardiopulmonary bypass to reduce the incidence of acute kidney injury after cardiac surgery. Investigators will also evaluate the safety and impact of pulsatile flow on clinical outcomes compared to non-pulsatile flow during cardiopulmonary bypass.",[497,498,26,499],"Acute Kidney Injury","Hemolysis","Surgery","2025-05-19",{"date":502,"type":41},"2025-05-21",{"date":500,"type":41},{"date":505,"type":22},"2028-10",{"name":507,"class":48},"University of Colorado, Denver",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":333,"enrollmentInfo":515,"targetDuration":4,"studyType":119,"phases":517,"briefSummary":518,"conditions":519,"keywords":521,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":531,"locationsCount":534},"100515995","phase-2-telitacicept-for-the-treatment-of-connective-tissue-disease-associated-thrombocytopenia-100515995","NCT05998759","Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","A Randomized, Double-blind Placebo-controlled Study of Recombinant Human B Lymphocyte Stimulating Factor Receptor-Fc Fusion Protein for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","Inclusion Criteria:\n\n* Subjects who have been diagnosed with connective tissue disease (CTD)-associated thrombocytopenia. And CTD includes primary Sjögren syndrome (according to the 2002 American College of Rheumatology (ACR)\u002F European League against Rheumatism (EULAR) classification criteria), systemic lupus erythematosus (SLE, according to the 1997 or the 2009 ACR classification criteria), and undifferentiated connective tissue disease (according to the 1999 international classification criteria)\n* Refractory thrombocytopenia defined as:\n\nEither: Failure to maintain sustained remission after treatment by glucocorticoid and at least one immunosuppressant (i.e. cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, methotrexate, leflunomide and hydroxychloroquine, et al.) Or: Relapse during oral glucocorticoid tapering or after withdrawal\n\n* 50×10\\^9\u002FL\\>PLT\n* anti-nuclear antibody (ANA) positive (≥1:80, any karyotype) detected in the laboratory of each research center\n* Standard therapy should be maintained stable for at least 14 days prior to the first dose of the experimental drug or placebo. Standard therapy refers to the following treatment (monotherapy or in combination): glucocorticoid, hydroxychloroquine, and other immunosuppressants (i.e. cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, methotrexate and leflunomide, et al.)\n* Signed informed consent form, willing or able to participate in all required study evaluations and procedures\n\nExclusion Criteria:\n\n* Vital organ lethal bleeding (including but not limited to central nervous system bleeding, digestive tract bleeding) at screening, or intracranial bleeding 6 months prior to screening\n* Antiphospholipid syndrome, thrombotic thrombocytopenia purpura, hemolytic uremic syndrome, or thrombocytopenia secondary to other causes (such as sepsis, Epstein-Barr virus infection, cytomegalovirus infection, Corona Virus Disease-19 (COVID-19) infection, drugs, etc.)\n* Hematopoietic system disorders, such as myelodysplastic syndrome, paroxysmal sleep hemoglobinuria, aplastic anemia, leukemia, lymphoma, myelofibrosis and so on\n* Severe cardiovascular system disease, including: unstable or uncontrollable disease or condition affecting the function of the heart (such as angina pectoris, congestive heart failure, uncontrolled hypertension or arrhythmia)\n* Arteriovenous thromboembolism events\n* Receiving antiplatelet or anticoagulant therapy at screening\n* Clinically significant electrocardiogram changes\n* corrected Q-T interval (QTc)\\>450ms for male, QTc\\>470ms for female\n* Severe pulmonary disease, including: unstable or uncontrollable disease or condition affecting respiratory function \\[e.g., diffuse alveolar hemorrhage, severe pulmonary hypertension, severe pulmonary interstitial disease (peripheral blood oxygen saturation \\\u003C92% at rest without oxygen, or forced vital capacity (FVC)\\\u003C50%, or carbon monoxide diffusing capacity (DLCO)\\\u003C50%)\\]\n* Severe kidney disease, including: severe lupus nephritis (urinary protein \\> 6 g\u002F24 hours or endogenous creatinine clearance \\\u003C 30 ml \u002Fmin) 8 weeks prior to randomization, active nephritis requiring current protocol disallowed drugs, severe renal insufficiency requiring hemodialysis or prednisone ≥100mg\u002F day (or equivalent) for ≥14 days\n* SLE or non-SLE related central nervous system disease (including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident, encephalitis, central nervous system vasculitis) 8 weeks prior to randomization\n* Active hepatitis, a history of severe liver disease. Subjects positive for hepatitis B surface antigen (HBsAg) or antibodies to hepatitis C virus are excluded. As for subjects with antibodies to hepatitis B core antigen (HBcAb), further hepatitis B virus (HBV)-DNA should be tested. If HBV-DNA is negative, subjects could be enrolled; otherwise, subjects should be excluded\n* Abnormal laboratory results (including but not limited to: alanine aminotransferase (ALT) or aspertate aminotransferase (AST)≥3×ULN (upper limit of normal), white blood cell count \\\u003C1.5×10\\^9\u002FL)\n* Subjects with known active infections (e.g., shingles, COVID-19, HIV, active tuberculosis, etc.), and active or recurrent gastrointestinal ulcers\n* Pregnant or lactating women, and subjects with a during plan during the trial\n* Allergic reaction: history of allergic reactions to human biological products\n* Treatment with B cell-targeting agents such as Rituximab or Epratuzumab or Belimumab six months prior to randomization\n* Treatment with tumor necrosis factor (TNF) inhibitors or TNF-receptor blockers six months prior to randomization\n* Participating in clinical trial 28 days or 5 drug half-lives of the investigational agents prior to randomization\n* Received live vaccine 28 days prior to randomization\n* Treatment with unstable dosage of thrombopoietin receptor agonists such as Eltrombopag or Romiplostim 14 days prior to randomization\n* Subjects with depression or suicidal thoughts\n* Previous treatment with telitacicept\n* B cell targeting drug therapy is not tolerated or responsive\n* Investigator considers candidates not appropriating for the study",{"count":516,"type":22},296,[148],"The goal of this clinical trial is to evaluate the efficacy and safety of Telitacicept for the treatment of connective tissue disease-associated thrombocytopenia.",[520,26],"Connective Tissue Diseases",[520,26,522,523,524],"biological agents","B cell","targeted therapy","2025-05-03",{"date":527,"type":41},"2025-05-06",{"date":529,"type":41},"2023-12-02",{"date":461,"type":22},{"name":532,"class":533},"Beijing Hospital","OTHER_GOV",23,{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":119,"phases":544,"briefSummary":545,"conditions":546,"keywords":547,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":49},"100586284","phase-2-the-study-of-different-cycles-of-high-dose-dexamethasone-in-the-treatment-of-itp-100586284","NCT06913374","The Study of Different Cycles of High-dose Dexamethasone in the Treatment of ITP","Dicycle Versus Tri-cycle High-dose Dexamethasone in Adult ITP: a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Participant must be at least 18 years of age at the time of the screening.\n* Participant may be male or female.\n* Participant has a confirmed diagnosis of newly diagnosed ITP according to the 2019 International Working Group assessment at screening, and has a baseline platelet count of less than 30 × 10\\^9 cells per L or had bleeding manifestations, or both.\n\nExclusion Criteria:\n\n* Participant has evidence of a secondary cause of immune thrombocytopenia (e.g. leukemia, lymphoma, common variable immune- deficiency, systemic lupus erythematosus, autoimmune thyroid disease, past medical history of untreated H. pylori infection) or to drug treatments (e.g. heparin, quinine, antimicrobials, anticonvulsants) or participant has a multiple immune cytopenia, e.g. Evan's syndrome.\n* Participant has clinically life-threatening bleeding (e.g. central nervous system bleeding, menorrhagia with significant drop in hemoglobin).\n* Participant has a history of coagulopathy disorders other than ITP.\n* Participant has a history of arterial or venous thromboembolism (e.g. stroke, transient ischemic attach, myocardial infarction, deep vein thrombosis or pulmonary embolism) within the 6 months prior to randomization or requires anticoagulant treatment.\n* Participant has 12-lead ECG with changes considered to be clinically significant upon medical review at baseline.\n* Participant has severe renal impairment (glomerular filtration rate less than 45ml\u002Fmin\u002F1.73 m2).\n* Participant has 3 × upper limit of normal of any of the following: alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase.\n* Participant with any of the following conditions: severe immunodeficiency, active or previous malignancy, human immunodeficiency virus (HIV), hepatitis B or C virus infection, pregnancy or lactation.",{"count":543,"type":22},118,[148,287],"Primary immune thrombocytopenia is an autoimmune disorder characterised by decreased platelet counts and increased bleeding risk. Corticosteroids have been the standard initial treatment of primary immune thrombocytopenia for more than 30 years. The aim of this randomized controlled trial is to compare the efficacy and safety of high-dose dexamethasone in treating new-diagnosed primary immune thrombocytopenia (ITP) in di-cycle and tri-cycle.",[26],[207,548],"Dexamethasone","2025-04-06",{"date":551,"type":41},"2025-04-08",{"date":553,"type":22},"2025-05-01",{"date":555,"type":22},"2027-05-30",{"name":557,"class":48},"Shandong University",{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":565,"enrollmentInfo":566,"targetDuration":4,"studyType":119,"phases":568,"briefSummary":569,"conditions":570,"keywords":574,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":49},"100534970","phase-1-ucmsc-exo-for-chemotherapy-induced-myelosuppression-in-acute-myeloid-leukemia-100534970","NCT06245746","UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia","A Single-center, Prospective Trial of the Safety and Efficacy of UCMSC-Exo in Consolidation Chemotherapy-induced Myelosuppression in Patients With Acute Myeloid Leukemia After Achieving Complete Remission","Inclusion Criteria:\n\n1. Aged between 18 and 60 years old;\n2. Acute myeloid leukemia (AML, AML subtype M3 excluded) diagnosed according to the 2022 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, who have achieved complete remission (CR1) and are going to receive consolidation therapy (cytarabine or cytarabine-based combined regimen, the cycle of consolidation therapy is not limited);\n3. The participant or his\u002Fher legal guardian is adequately informed of the nature and risks of the study, voluntarily participates in the study with signed informed consent;\n4. Male or female;\n5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2 (by the day chemotherapy is initiated)\n6. Estimated survival of at least 3 months;\n7. Adequate major organ function:\n\n   1. Respiratory function: indoor oxygen saturation of at least 95%;\n   2. Cardiac function: ejection fraction of left ventricular of at least 45%;\n   3. Hepatic function: alanine aminotransferase\u002Faspartate aminotransferase of at most 2.5 times\u002Fupper limit of normal value and serum total bilirubin of at most 1.5 times\u002Fupper limit of normal value;\n   4. Renal function: Serum creatinine of at most 1.5 times\u002Fupper limit of normal value;\n8. Participants who do not receive any type of anti-cancer therapy within 2 weeks before enrollment (radiation therapy, chemotherapy and\u002For immune therapy, et al.), and treatment-associated toxicities induced by previous therapy has recovered to Grade 1 or below (except for low grade toxicities such as alopecia).\n9. For female participants, they should be surgical sterilized or post-menopausal, or agree to utilize a medically recognised method of contraception (such as intrauterine device, condom) during treatment period of the study and within 6 months after the end of treatment period of the study; For male participants, they should be surgical sterilized or agree to utilize a medically recognised method of contraception (such as intrauterine device, condom) during treatment period of the study and within 6 months after the end of treatment period of the study;\n\nExclusion Criteria:\n\n1. Central nervous system manifestations of acute myeloid leukemia at diagnosis;\n2. Secondary acute myeloid leukemia;\n3. Myelosuppression induced by conditions other than anti-cancer therapy;\n4. Previous radiation therapy performed on sternum or pelvis;\n5. Specifically diagnosed and uncontrolled infection at enrollment (Uncontrolled is defined as exhibiting ongoing signs and symptoms of infection without improvement despite anti-infective agents) ;\n6. Uncontrolled active bleeding at enrollment;\n7. Severe underlying comorbidities affecting survival, including cachexia, severe malnutrition, etc;\n8. Estimated survival of at most 48 hours;\n9. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection;\n10. History of or current human immunodeficiency virus (HIV) infection;\n11. Syphilis infection;\n12. Continuous usage of immunosuppressants or received organ transplantation in the last 6 months;\n13. Participation in clinical trials of other drugs within 6 weeks before enrollment;\n14. Previous participation in clinical stem cell or exosome research;\n15. Receive any agent concurrently with UCMSC-Exo infusion which inhibits cell division (hydroxyurea, low-dose cytarabine or methotrexate, etc) ;\n16. Severe allergic constitution, or known or suspected allergy to the study drug and its components;\n17. Known contraindication to receiving hematopoietic growth factors, transfusion of blood components, anti-infective agents;\n18. Female participants who are pregnant or breast feeding;\n19. Participants suffering from mental illness;\n20. Presence of drug abuse\u002Faddiction;\n21. History of other malignancies other than hematological malignancies within 3 years;\n22. Participants without signed informed consent;\n23. Participants with poor compliance and are unable to complete the whole course of the study;\n24. Participants with circumstances that, in the opinion of the investigator, may increase the risk of the participants or interfere with conduct of the clinical trial and the judgment of results (excessive tension, sensitivity or cognitive impairment, etc) ;\n25. Participants with other circumstances that are ineligible for enrollment in this study, in the opinion of the investigator.","60 Years",{"count":567,"type":22},9,[415],"The purpose of the study is to explore the safety and efficacy of UCMSC-Exo in consolidation chemotherapy-induced myelosuppression in patients with acute myeloid leukemia after achieving complete remission.",[571,267,265,26,572,573],"Acute Myeloid Leukemia","Infections","Bleeding",[575,576,577,578,66,579,580,581,582],"umbilical cord derived mesenchymal stem cells exosomes","chemotherapy-induced myelosuppression","neutropenia","anemia","infections","bleeding","acute myeloid leukemia","chemotherapy","2025-03-20",{"date":585,"type":41},"2025-03-21",{"date":587,"type":41},"2025-02-26",{"date":589,"type":22},"2027-02",{"name":591,"class":48},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":119,"phases":600,"briefSummary":601,"conditions":602,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":377},"100454620","phase-2-safety-and-efficacy-of-zanubrutinib-in-the-treatment-of-antiphospholipid-syndrome-with-secondary-thrombocytopenia-100454620","NCT05199909","Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia","Prospective, Single Arm and Open Clinical Observation of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia","Inclusion Criteria:\n\n* Age 18 and above, male or female；\n* Diagnosis of antiphospholipid syndrome；\n* Failure to receive glucocorticoid treatment in the past (the curative effect cannot be maintained, or recurs, or cannot be tolerated); Can not choose other second-line treatment, such as rituximab, cyclosporine, cyclophosphamide, etc.; Or rituximab, cyclosporine and other treatments are ineffective, relapsed or intolerable;\n* Plt \\\u003C 30×10\\^9\u002FL；\n* Liver and kidney function, such as ALT, AST, BUN, SCR \\\u003C 1.5 × upper limit of normal value, passing physical examination;\n* ECOG physical state score ≤ 2 points；\n* Cardiac function of the New York Society of Cardiac Function ≤ 2；\n* Signed and dated written informed consent.\n\nExclusion Criteria:\n\n* Uncontrollable primary diseases of important organs, such as malignant tumors, liver failure, heart failure, renal failure and other diseases；\n* HIV positive;\n* Accompanied by uncontrollable active infection, including hepatitis B, hepatitis C, cytomegalovirus, EB virus and syphilis positive;\n* Accompanied by extensive and severe bleeding, such as hemoptysis, upper gastrointestinal hemorrhage, intracranial hemorrhage, etc.;\n* At present, there are heart diseases, arrhythmias that need treatment or hypertension that researchers judge is poorly controlled;\n* Patients with thrombotic diseases such as new pulmonary embolism and unstable period of various arteriovenous thrombosis;\n* Those who have received allogeneic stem cell transplantation or organ transplantation in the past;\n* Patients with mental disorders who cannot normally obtain informed consent and conduct trials and follow-up;\n* Patients whose toxic symptoms caused by pre-trial treatment have not disappeared;\n* Other serious diseases that may limit the subject's participation in this test (such as diabetes; Severe cardiac insufficiency; Myocardial obstruction or unstable arrhythmia or unstable angina pectoris in recent 6 months; Gastric ulcer，etc.);\n* Patients with septicemia or other irregular severe bleeding;\n* Pregnant women, suspected pregnancies (positive pregnancy test for human chorionic gonadotropin in urine at screening) and lactating patients.",{"count":472,"type":22},[148],"To evaluate the safety and efficacy of zanubrutinib in the treatment of antiphospholipid syndrome with secondary thrombocytopenia in 10 patients.",[476,26,603],"Treatment","2025-02-20",{"date":606,"type":41},"2025-02-24",{"date":608,"type":41},"2022-01-25",{"date":610,"type":22},"2025-06-30",{"name":483,"class":48},{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":616,"acronym":4,"eligibilityCriteria":617,"healthyVolunteers":224,"sex":18,"minAge":19,"maxAge":565,"enrollmentInfo":618,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":619,"conditions":620,"keywords":622,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":624,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":49},"100362351","evaluation-of-immune-status-before-and-after-splenectomy-in-immune-thrombocytopenia-patients-100362351","NCT03998059","Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia Patients","Inclusion Criteria:\n\n* Aged 18 to 60 years old, male or female;\n* Conform to the diagnostic criteria of immune Thrombocytopenia (ITP)\n* Needed splenectomy;\n* People who are willing to sign the informed consent voluntarily and follow the research program.\n\nExclusion Criteria:\n\n* Secondary thrombocytopenic purpura;\n* Patients with poor compliance;\n* Researchers believe that patients should not participate in the test of any other condition.",{"count":260,"type":22},"Evaluation of immune status before and after splenectomy in immune thrombocytopenia patients.",[26,621],"Splenectomy",[26,623],"splenectomy",{"date":606,"type":41},{"date":626,"type":41},"2019-01-23",{"date":628,"type":22},"2025-07-23",{"name":483,"class":48},{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":4,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":637,"targetDuration":4,"studyType":119,"phases":638,"briefSummary":639,"conditions":640,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":377},"100567846","phase-2-lusutrombopag-combined-with-recombinant-human-thrombopoietin-for-the-treatment-of-thrombocytopenia-in-patients-with-chronic-liver-disease-destined-to-undergo-elective-invasive-surgery-100567846","NCT06673498","Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery","Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery: a Prospective, Multicentre, Single-arm Clinical Study","Inclusion Criteria:\n\n* Ability to understand the study and willingness to comply with all study procedures by voluntarily signing an informed consent form prior to screening.\n* Male or female, 18 years of age or older at the time of signing the informed consent form.\n* Patients with chronic liver disease.\n* Baseline platelet count ≤ 35 x 109\u002FL prior to enrolment on day 1.\n* Proposed elective invasive surgery that meets the following conditions: - Platelet transfusion may be required - Expected to be performed between days 9 and 15 after enrolment - Excludes extremely high-risk surgical operations such as open abdomen, open chest, open skull, and direct cardiac surgery.\n* Eastern Collaborative Oncology Group (ECOG) Physical Status (PS) score of 0 or 1.\n* According to the researcher, it will be able to fulfil the requirements of this study.\n* Male patients who are infertile or who agree to use adequate contraception (including the use of condoms containing spermicides) from the start of screening until completion of the post-treatment phase.\n* Female patients who are not menopausal or surgically sterilised need to agree to the use of highly effective contraception (including implants, injectable contraception, combined hormonal contraception \\[including vaginal rings\\], intrauterine devices, or partner-performed vasectomies) from the start of the screening until the completion of the end-of-treatment phase. The use of barrier contraception with or without spermicide, double barrier contraception and oral contraceptives alone is not adequate.\n\nExclusion Criteria:\n\n* Presence of any of the following diseases: - Haematopoietic tumours - Aplastic anaemia - myelodysplastic syndrome - myelofibrosis - Congenital thrombocytopenia - Drug-induced thrombocytopenia - Immune thrombocytopenia - Systemic infections requiring treatment, except viral hepatitis\n* Any solid malignancy with the following conditions: - Patients will require systemic chemotherapy, targeted therapy, immunotherapy, traditional herbal medicine or radiotherapy for that malignancy during the study period - Malignancy with lymph node metastasis, distant metastasis or peripheral organ invasion - Exceptions are: - Malignancy is a therapeutic target for the first invasive surgery - Non-melanoma skin cancers, intramucosal cancers, or carcinoma in situ that do not require any treatment during the study period.\n* History of liver transplantation.\n* Previous or current thrombosis or pre-thrombotic state (e.g., cerebral infarction, cardiac infarction, angina pectoris, coronary stenting, angioplasty, coronary artery bypass grafting, congestive heart failure \\[New York Heart Association {NYHA} class III\u002FIV\\], cardiac arrhythmia \\[e.g., atrial fibrillation\\] known to increase the risk of thromboembolic events, pulmonary thromboembolism, deep venous thrombosis, or disseminated vascular (intravascular coagulation syndrome).\n* Presence of any of the following conditions at screening: - Symptoms of hepatic encephalopathy with Child-Pugh Hepatic Encephalopathy Score 3 (occasional coma), with or without treatment for hepatic encephalopathy - Ascites uncontrolled by medications - Total bilirubin \\> 3 mg\u002FdL\n* Presence of history or evidence of a disease with bleeding risk (e.g. coagulation factor deficiency or vascular haemophilia factor vWF deficiency).\n* History or evidence of any of the following disorders: - Congenital thrombophilia (e.g., antithrombin deficiency, protein C deficiency, protein S deficiency, or coagulation factor \\[coagulation factor V Leiden\\] mutation) - Acquired thrombophilia (e.g., antiphospholipid antibody syndrome, paroxysmal nocturnal haemoglobinuria, hyperhomocysteinemia, or elevated coagulation factor VIII) - Budd-Chiari syndrome\n* Portal vein tumour embolism.\n* Ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) within 28 days prior to enrolment showing portal vein thrombosis, or a history of portal vein thrombosis.\n* Upper gastrointestinal endoscopy within 180 days prior to enrolment showing bleeding due to untreated gastro-oesophageal varices or the need to undergo treatment (except for patients in whom the first invasive procedure was performed to treat gastro-oesophageal varices).\n* Prior to enrolment, the bleeding score was ≥ grade 2 according to the World Health Organization (WHO) Bleeding Scale.\n* Use of any of the following medications or treatments within 90 days prior to enrolment: - Antineoplastic agents, excluding transcatheter arterial chemoembolisation (TACE) and oil iodide embolisation - Interferon agents - Radiotherapy - Radiotherapy - Any experimental drug\n* Known hypersensitivity to the test drug or any of its excipients.\n* Positive human immunodeficiency virus antigen\u002Fantibody test at screening.\n* Women who are pregnant or breastfeeding.\n* Patients deemed ineligible by the investigator for any other reason.",{"count":21,"type":22},[148],"To assess the efficacy and safety of lusutrombopag combined with recombinant human thrombopoietin for the treatment of thrombocytopenia in patients with chronic liver disease destined to undergo elective invasive surgery.",[26],"2024-11-02",{"date":643,"type":41},"2024-11-05",{"date":645,"type":22},"2024-11-10",{"date":647,"type":22},"2025-11-30",{"name":649,"class":533},"Anhui Provincial Hospital",{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":656,"eligibilityCriteria":657,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":145,"enrollmentInfo":658,"targetDuration":4,"studyType":119,"phases":660,"briefSummary":661,"conditions":662,"keywords":664,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":667,"lastUpdatePostDateStruct":668,"startDateStruct":670,"completionDateStruct":672,"leadSponsor":674,"locationsCount":676},"100531655","phase-2-efficacy-and-safety-of-avatrombopag-in-the-treatment-of-thrombocytopenia-after-haplo-hsct-100531655","NCT06202625","Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT","Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haploidentical Hematopoietic Stem Cell Transplantation: Prospective, Multi-center, Double-blinded, Randomized Placebo-controlled Study","Haplo-HSCT","Inclusion Criteria:\n\n1. Male or female, aged between 18-65 years;\n2. PLT\\\u003C20×10\\^9\u002FL or transfusion dependent on +D7 after haplo-HSCT;\n3. Agree to receive the treatment of avatrombopag after Haplo-HSCT and sign the informed consent form.\n\nExclusion Criteria:\n\n1. With active infection;\n2. ALT or AST\\>3ULN, or total Bil\\>2ULN\n3. Ccr\\\u003C50 mL\u002Fmin;\n4. With the history of arteriovenous thrombosis;\n5. With history of cardiovascular disease (such as NYHA Class III\u002FIV congestive heart failure, arrhythmia that increases the risk of thromboembolic events \\[such as atrial fibrillation\\] and angina), and subjects who have undergone coronary stent implantation, angioplasty, or coronary artery bypass grafting;\n6. With treatment of drugs to promote platelet production two weekes before enrollment, including but not limited to rhTPO and TPO-RA;\n7. HBsAg or anti-HCV or anti-HIV positive;\n8. Known to be allergic to avatrombopag and any of its excipients;\n9. With secondary or multiple HSCT;\n10. Females who were pregnant or breastfeeding or who had fertile ability but refuse to take effective contraceptive measures during and one month after this trial;\n11. With any other clinical trial of investigational product or device within 30 days prior to the baseline visit, except for observational study;\n12. Deemed unsuitable for enrollment by the investigator for any history of or concomitant medical condition.\n13. Concomitant medication:The rhIL-11, rhTPO or TPO-RA(such as eltrombopag, hetrombopag and romiplostim) and desitabine, etc. were not allowed for use during this trial.",{"count":659,"type":22},142,[148,287],"In this study, investigators aim to evaluate the efficacy of avatrombopag in thrombocytopenic patients after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) through a prospective, multi-center, double-blinded, randomized placebo-controlled clinical trial.",[26,663],"Stem Cell Transplant Complications",[26,665,666],"hematopoietic stem cell transplantation","haploidentical","2024-09-29",{"date":669,"type":41},"2024-10-01",{"date":671,"type":41},"2024-05-13",{"date":673,"type":22},"2025-10-30",{"name":675,"class":48},"Peking University People's Hospital",14]